Concepedia

Cheryl Napier

CN

Statistics

Publications

11

Citations

641

H-Index

10

Active since

1997

Affiliations

Johnson & Johnson (United States)(Current)

Array BioPharma (United States)

Cheryl Napier is an author at Johnson & Johnson (United States) specializing in oncology, cancer pharmacology, and medicine.

Publications per year

1997–2018

11

Publications

11

Sequence- and Region-Specificity of Oxaliplatin Adducts in Naked and Cellular DNA

Jan M. Woynarowski, William G. Chapman, Cheryl Napier et al. · Molecular Pharmacology · 1998 · 240 citations

Medicine, Molecular Biology, Oncology +12

The <i>In vitro</i> and <i>In vivo</i> Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases

Stuart L. Emanuel, Catherine A. Rugg, Robert H. Gruninger et al. · Cancer Research · 2005 · 125 citations · Full text

Medicine, Oncology, Pharmacology +13

Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114)

Jan M. Woynarowski, Cheryl Napier, Steven K. Koester et al. · Biochemical Pharmacology · 1997 · 100 citations

Medicine, Oncology, Pharmacology +13

A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models

Stuart L. Emanuel, Robert H. Gruninger, Angel R. Fuentes‐Pesquera et al. · Molecular Pharmacology · 2004 · 41 citations

Medicine, Oncology, Pharmacology +15

Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors

Stuart L. Emanuel, Terry V. Hughes, Mary Adams et al. · Molecular Pharmacology · 2007 · 36 citations

Medicine, Medicinal Chemistry, Pharmacology +16

1–5 of 11